



## ASX ANNOUNCEMENT

October 3<sup>rd</sup>, 2011

---

### **Appointment of Dr. Mervyn Cass as Company Director**

The Board of Directors of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has with great pleasure appointed Dr. Mervyn Cass as a non-executive Director of the Company. An ASX Appendix 3X for Dr. Cass is attached to this announcement.

Dr. Cass is a practising medical practitioner and, after 28 years as the senior partner in an occupational medical practice in Port Melbourne, accepted the appointment as Medical Director of a plastic surgery centre in 1996. He was the founding Chairman of the Australasian Occupational Medical Group and was a Director of Wolfe Research Pty. Ltd., a private medial biotech company associated with RMIT University. He has been an advisor to the Victorian Government on Workers' Compensation and Radiological Standards in general practice. Dr. Cass is currently an executive member of the Jewish Community Council of Victoria, the roof body of the Victorian Jewish Community.

The Company's Chairman Mr. Sid Hack said, "The Directors of Genetic Technologies are delighted that Mervyn has agreed to join the Board. His substantial experience in the fields of medicine, women's health and restorative surgery will be of great practical and immediate value in the growth and development of the Company's cancer diagnostics business. We very much look forward to working with Mervyn at this important time in the history of the Company."

---

#### FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Paul D.R. MacLeman  
Chief Executive Officer

Genetic Technologies Limited  
Phone: +61 3 8412 7000

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

Name of entity	<b>Genetic Technologies Limited</b>
A.B.N.	<b>17 009 212 328</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	<b>Dr. Mervyn Cass</b>
Date of appointment	<b>30 September 2011</b>

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
None

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3X**  
**Initial Director's Interest Notice**

---

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Number &amp; class of Securities</b>
Cassen Nominees Pty. Ltd. <Cass Family Super Fund A/C>  Member / Beneficiary	473,667 fully paid ordinary shares

**Part 3 – Director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

**Dated: 3 October 2011**

For personal use only